Indian firm Natco Pharma has signed an agreement with Mabxience, a unit of Swiss-based Chemo Sa Lugano, to purchase four mAb drug substances from Chemo and use them to manufacture finished dosage pharmaceutical formulations.
Three of the four products – Trastuzumab, Bevacizumab, and Rituximab – belong to the oncology segment, while Etanercept is used to treat autoimmune diseases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the agreement, Natco will manufacture the products, undertake local clinical trials, file registration of dossiers, apply for market authorisations, and commercialise them in India and other Asian countries.
Natco expects to complete the initiative in two or three years.
